Several lines of evidence lend support to the view that, far from being an inert molecule, serum uric acid (UA) correlates with blood pressure levels and can predict the future development of hypertension. To date, it is unclear whether the role of this molecule goes beyond hypertension development and extends to subsequent target organ damage (TOD). To this end, we sought to investigate the relationship of serum UA levels with left ventricular mass and geometry, which constitute markers of TOD, in a large cohort of newly diagnosed, nevertreated hypertensive patients.
A total of 1225 patients with a new diagnosis of arterial hypertension (systolic blood pressure X140 mm Hg and/or diastolic blood pressure X90 mm Hg on two different occasions) for which they had never received treatment were included, after a retrospective search of our hypertension clinic's database. They underwent a standardized medical history and examination, laboratory tests and echocardiographic assessment. Carotid-femoral pulse wave velocity (PWV), an index of large artery stiffness, was measured as an additional surrogate of TOD. Participants with coronary artery disease, cerebrovascular disease, peripheral artery disease, systemic inflammatory disease and gout were excluded. Use of anti-inflammatory agents, anticoagulants, antidiabetics, lipid and UA-lowering drugs were also exclusion criteria. Blood samples were obtained after a 12-h fast. Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. PWV was measured non-invasively using a validated device (Complior, Artech Medical, Pantin, France). 1 Left ventricular mass index (LVMI) and relative wall thickness were assessed by echocardiography. M-mode imaging was used for wall-thickness measurements. LVMI was calculated using the Devereux formula; 2 left ventricular hypertrophy (LVH) was defined as a LVMIX125 g per m 2 in men and X110 g per m 2 in women. Relative wall thickness was calculated as (septal wall thickness þ posterior wall thickness)/left ventricular diastolic diameter; patients with relative wall thickness 40.44 were classified as having a concentric left ventricular geometric pattern. Participants gave informed consent to participate in the study, which was approved by the local Ethics Committee.
Statistical normality was checked using the Kolmogorov-Smirnov test. Normally distributed continuous variables are presented as mean±s.d. Non-normally distributed variables are presented as median (25th-75th percentile) and were log transformed for multiple linear regression analyses. Categorical variables are reported as frequencies and percentages. The Mann-Whitney U test was used for group comparisons. Correlations among variables were examined by Spearman's r correlation coefficient. Preliminary analyses were performed to ensure no violation of the assumptions of normality, linearity and homoscedasticity. To explore the relationship of UA levels and LVMI independently of possible confounders, we performed standard multiple linear regression analyses. LVMI was the dependent variable and UA an independent variable; smoking status, sex, diabetes mellitus (dichotomous variables) and age, total cholesterol, estimated glomerular filtration rate, mean arterial pressure and C-reactive protein were used as covariates. A second analysis followed with the addition of PWV among the aforementioned variables. SPSS 13.0 (SPSS, Chicago, IL, USA) was used. A two-tailed P-value o0.05 was considered significant.
The characteristics of the population are presented in an online Supplementary Table. Their median age was 53 (interquartile range: 46, 61) years, 59.4% were men and 41.6% were smokers. Regarding UA and carotid-femoral PWV levels, these were 5.25 (4.2, 6.2) mg dl À1 and 7.9 (7.05, 9.1) m sec À1 , respectively. In all, 41.7% of patients had a normal left ventricle and 16.3% demonstrated concentric remodeling; 17.4% and 24.6% had concentric and eccentric LVH, respectively. UA levels were significantly higher in patients with LVH compared with patients with normal ventricular mass (5.5 vs 5.0 mg dl À1 , respectively, Po0.001). A positive correlation between UA and LVMI (r ¼ 0.313, Po0.001) was observed, suggesting that increased urate levels are associated with a higher myocardial mass. In standard multiple linear regression analysis, UA levels were independently associated with LVMI after adjusting for possible confounders (standardized regression coefficient Table 1 ). However, when PWV was added to the model as an additional independent variable, UA lost its independent association, as an independent association of PWV with LVMI emerged (standardized regression coefficient b ¼ 0.038, P ¼ 0.211 for UA; standardized regression coefficient b ¼ 0.174, Po0.001 for PWV; adjusted R 2 ¼ 0.314, Model 2, Table 1 ). Regarding left ventricular geometry, UA levels did not differ among concentric and eccentric left ventricular patterns (5.3 vs 5.2 mg dl À1 , respectively, P ¼ 0.534), neither did they correlate with relative wall thickness values (r ¼ 0.015, P ¼ 0.594).
Elevated levels of UA are implicated in the pathogenesis of hypertension and are a marker of impaired renal function. 3 Similarly, LVH is an adverse predictor of outcomes, as it increases susceptibility to arrhythmias and myocardial dysfunction. Cellular changes induced by hypertrophy lead to abnormal relaxation and passive filling, which manifest as diastolic dysfunction and can progress to heart failure. Following diastolic heart failure, systolic function may consequently be hampered.
Conflicting data exist regarding the relationship of UA with LVH in hypertension. Lack of consensus may be attributed to different methodologies for assessing LVH (electrocardiographic, 4 radiographic 5 or echocardiographic 6 criteria), use of antihypertensive medications and presence of commorbidities that may blunt relationships. To the best of our knowledge, this is the first study to explore the interplay of echocardiographic measures of left ventricular geometry with UA levels and arterial stiffness in never-treated hypertension.
A number of pathophysiological mechanisms link elevated UA levels to the development of LVH, a hallmark of myocardial damage. In experimental models, cardiomyocyte growth and interstitial fibrosis are ascribed to activation of the reninangiotensin-aldosterone system; 7 UA activates the renin-angiotensin-aldosterone system both at the local and systemic levels. Hyperuricemia may act through indirect mechanisms as well, by promoting inflammation 8 and increasing oxidative status. 9 Large artery stiffness is both a marker and maker of hypertensive sequelae. Our group has previously reported that UA levels are independently associated with PWV, 1 a measure of arterial stiffness that has shown to be an independent predictor of outcomes. 10 In this study, despite the fact that PWV and UA levels are significantly associated with LVMI when separately entered in multivariable models, inclusion of both variables results in a loss of significance for the interaction effect of UA. This intriguing finding may help disentangle the complex interplay of UA, LVH and PWV, as it suggests that UA leads to LVH partly through an increase in arterial stiffness, which is causally related to LVH. Notwithstanding, whether UA leads to arterial stiffening and LVH or is merely a marker of underlying processes remains to be tested in prospective studies. George et al. 11 have challenged the role of UA by showing that it is the inhibition of xanthine oxidase that leads to better endothelial responses, and not just UA-lowering strategies by means of uricosuric drugs. Therefore, more data to support or refute a direct pathophysiological role of UA on arterial stiffness and LVH are needed.
Current guidelines advocate screening of patients for subclinical TOD; once such changes appear, aggressive pharmacological management is required for deferring disease progression. The finding of increased UA levels in hypertensive patients should serve as a harbinger of TOD and alert for strict blood pressure control. Renin-angiotensin-aldosterone system inhibitors can effectively tackle the triad of increased blood pressure, LVH and arterial stiffness; certain agents further extend their beneficial role by concomitantly lowering UA levels. 12 However, prospective studies are needed, and the hypothesis that UA-lowering regimes can result in regression of LVH and hypertension also remains open to question. 
